World’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
DetailsRecently, t he Antibody-Drug Conjugates (ADCs) program’s‘Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine Conjugates for Injection’ (BAT8001) was approved for clinical trials in China. BAT8001 is suitable for multiple cancer disease indications, including HER2 over-expressed meta...
On September 5 2016,Bio-thera reached a strategic cooperation agreement with world class CRO, Quintiles. Under agreement with Bio-Thera, Quintileswith provide all-around international clinicalstudy and filingcooperative supportfor new drugs developed by Bio-thera. The signing ceremony was held at th...
Great news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection (BAT1706 ) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosimilar clinical trials this year. BAT1706 is a bevacizumab biosimilar ind...